Translational Genomics Research Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.tgen.org
ARPIs Show Similar Efficacy in mHSPC Regardless of Disease Volume; Drug Selection Should Focus on Patient-Specific Factors
A systematic review of phase 3 trials reveals that all androgen receptor pathway inhibitors (ARPIs) demonstrate comparable efficacy outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients regardless of disease volume or metastasis timing.
© Copyright 2025. All Rights Reserved by MedPath